Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.

Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, Farra Y, Young D, Grever M.

Clin Cancer Res. 2006 Jul 1;12(13):3997-4003.

PMID:
16818698
[PubMed - indexed for MEDLINE]
Free Article
2.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.

Clin Cancer Res. 2002 Mar;8(3):718-28.

PMID:
11895901
[PubMed - indexed for MEDLINE]
Free Article
3.

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.

Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6111-8.

PMID:
15447997
[PubMed - indexed for MEDLINE]
Free Article
4.

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.

Children's Oncology Group, Fouladi M, Furman WL, Chin T, Freeman BB 3rd, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM.

J Clin Oncol. 2006 Aug 1;24(22):3678-85.

PMID:
16877737
[PubMed - indexed for MEDLINE]
5.

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.

Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P.

Eur J Haematol. 2008 Sep;81(3):170-6. doi: 10.1111/j.1600-0609.2008.01102.x. Epub 2008 May 27.

PMID:
18510700
[PubMed - indexed for MEDLINE]
6.

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, Figg WD, Wainer I, Chaissang C, Li MZ, Hawkins MJ.

J Exp Ther Oncol. 2002 Nov-Dec;2(6):325-32.

PMID:
12440223
[PubMed - indexed for MEDLINE]
7.

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

Izquierdo MA, Bowman A, García M, Jodrell D, Martinez M, Pardo B, Gómez J, López-Martin JA, Jimeno J, Germá JR, Smyth JF.

Clin Cancer Res. 2008 May 15;14(10):3105-12. doi: 10.1158/1078-0432.CCR-07-1652.

PMID:
18483378
[PubMed - indexed for MEDLINE]
Free Article
8.

Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.

Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, Fouladi M, Freeman BB 3rd, Stewart CF, Houghton PJ.

Clin Cancer Res. 2006 Jan 1;12(1):223-34.

PMID:
16397046
[PubMed - indexed for MEDLINE]
Free Article
9.

A phase II study of depsipeptide in refractory metastatic renal cell cancer.

Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA.

Clin Genitourin Cancer. 2006 Jun;5(1):57-60.

PMID:
16859580
[PubMed - indexed for MEDLINE]
10.

Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.

Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, Soulieres D, Stewart D, Goel R, Charpentier D, Goss G, Tomiak E, Yau J, Jimeno J, Chiritescu G; National Cancer Institute of Canada Clinical Trials Group.

Ann Oncol. 2006 Sep;17(9):1371-8.

PMID:
16966366
[PubMed - indexed for MEDLINE]
Free Article
11.

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.

Eisen T, Thatcher N, Leyvraz S, Miller WH Jr, Couture F, Lorigan P, Lüthi F, Small D, Tanovic A, O'Brien M.

Lung Cancer. 2009 Apr;64(1):60-5. doi: 10.1016/j.lungcan.2008.06.017. Epub 2008 Aug 9.

PMID:
18692272
[PubMed - indexed for MEDLINE]
12.

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.

Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K.

Clin Cancer Res. 2006 Aug 1;12(15):4628-35.

PMID:
16899611
[PubMed - indexed for MEDLINE]
Free Article
13.

Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.

Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, López A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM.

Clin Cancer Res. 2008 Feb 15;14(4):1116-23. doi: 10.1158/1078-0432.CCR-07-4366.

PMID:
18281545
[PubMed - indexed for MEDLINE]
Free Article
14.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS.

J Clin Oncol. 2008 Jul 10;26(20):3403-10. doi: 10.1200/JCO.2007.15.9020.

PMID:
18612155
[PubMed - indexed for MEDLINE]
15.

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.

Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM.

Invest New Drugs. 2008 Feb;26(1):59-65. Epub 2007 Oct 16.

PMID:
17938863
[PubMed - indexed for MEDLINE]
16.

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.

Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panageas K, Wright JJ, Pandolfi PP, Nimer SD.

Clin Cancer Res. 2008 Feb 1;14(3):826-32. doi: 10.1158/1078-0432.CCR-07-0318.

PMID:
18245545
[PubMed - indexed for MEDLINE]
Free Article
17.

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.

Varker KA, Campbell J, Shah MH.

Cancer Chemother Pharmacol. 2008 Apr;61(4):661-8. Epub 2007 Jun 23.

PMID:
17589846
[PubMed - indexed for MEDLINE]
18.

Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.

Eisen T, Thomas J, Miller WH Jr, Gore M, Wolter P, Kavan P, Martín JA, Lardelli P.

Melanoma Res. 2009 Jun;19(3):185-92. doi: 10.1097/CMR.0b013e32832bbde6.

PMID:
19436178
[PubMed - indexed for MEDLINE]
19.

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.

Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D.

Melanoma Res. 2008 Aug;18(4):274-8. doi: 10.1097/CMR.0b013e328307c248.

PMID:
18626312
[PubMed - indexed for MEDLINE]
20.

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.

Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A.

J Clin Oncol. 2007 May 20;25(15):1979-85.

PMID:
17513804
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk